Research Analysts’ Recent Ratings Changes for Alkermes (ALKS)

A number of firms have modified their ratings and price targets on shares of Alkermes (NASDAQ: ALKS) recently:

• 11/13/2024 – Alkermes had its price target raised by analysts at Mizuho from $35.00 to $40.00. They now have an “outperform” rating on the stock.
• 11/5/2024 – Alkermes was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $36.00 price target on the stock, up previously from $25.00.
• 10/25/2024 – Alkermes had its price target lowered by analysts at Cantor Fitzgerald from $48.00 to $43.00. They now have an “overweight” rating on the stock.
• 10/25/2024 – Alkermes had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $37.00 price target on the stock, down previously from $38.00.
• 10/25/2024 – Alkermes had its price target lowered by analysts at JPMorgan Chase & Co. from $32.00 to $26.00. They now have a “neutral” rating on the stock.
• 10/25/2024 – Alkermes had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.
• 10/25/2024 – Alkermes had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $32.00 to $30.00. They now have a “buy” rating on the stock.
• 10/14/2024 – Alkermes had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.
• 10/10/2024 – Alkermes had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $48.00 price target on the stock.
• 9/16/2024 – Alkermes had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $48.00 price target on the stock.

Alkermes Stock Up 0.0 %

ALKS stock opened at $29.24 on Thursday. The company has a 50 day moving average of $27.71 and a two-hundred day moving average of $26.16. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 14.99, a PEG ratio of 0.98 and a beta of 0.47. Alkermes plc has a 12-month low of $22.06 and a 12-month high of $32.88. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Insider Buying and Selling

In other news, EVP Craig C. Hopkinson sold 10,471 shares of Alkermes stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total transaction of $309,208.63. Following the completion of the sale, the executive vice president now directly owns 99,238 shares in the company, valued at $2,930,498.14. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Alkermes news, EVP Craig C. Hopkinson sold 58,996 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the transaction, the executive vice president now directly owns 83,300 shares of the company’s stock, valued at $2,505,664. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Craig C. Hopkinson sold 10,471 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the completion of the sale, the executive vice president now directly owns 99,238 shares of the company’s stock, valued at $2,930,498.14. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.89% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alkermes

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in Alkermes by 74.7% during the third quarter. BNP Paribas Financial Markets now owns 149,493 shares of the company’s stock valued at $4,184,000 after purchasing an additional 63,939 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Alkermes by 365.5% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,882,936 shares of the company’s stock worth $52,704,000 after buying an additional 1,478,422 shares during the period. Dynamic Technology Lab Private Ltd grew its stake in Alkermes by 8.6% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 15,704 shares of the company’s stock valued at $440,000 after buying an additional 1,248 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Alkermes by 7.5% in the 3rd quarter. Fisher Asset Management LLC now owns 260,785 shares of the company’s stock worth $7,299,000 after acquiring an additional 18,147 shares during the period. Finally, Daiwa Securities Group Inc. lifted its position in Alkermes by 56.9% during the 3rd quarter. Daiwa Securities Group Inc. now owns 13,241 shares of the company’s stock worth $371,000 after acquiring an additional 4,800 shares during the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.